- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03872310
Cognitive Enhancement on Working Memory in Patients With Schizophrenia (CEWMPS)
A Study of Cognitive Enhancement of Transcranial Direct Current Stimulation on Working Memory in Patients With Schizophrenia
Study Overview
Status
Intervention / Treatment
Detailed Description
Schizophrenia is a chronic and disabling disease with a prevalence of 0.5%~1.5% in the general population. It's estimated 98% of patients with schizophrenia exhibit variable degrees of cognitive deficits which have been well established to be predictive of patient functioning. A number of treatments had been developed for cognitive enhancement in patients with schizophrenia, nevertheless none of them showed satisfying results.
Transcranial direct current stimulation (tDCS) is a safe and convenient treatment which has showed some evidence of beneficial effects on working memory (WM) in both healthy and neuropsychiatric populations. However, studies of tDCS for cognitive enhancement in patients with schizophrenia are still quiet limited. The results of our previous studies in healthy participants and patients with diabetic polyneuropathy suggest that the anodal tDCS over right dorsolateral prefrontal cortex (DLPFC) improved spatial WM capacity, particularly when task difficulty demands more complex mental manipulations and for the low-performing patients in baseline assessments. Thus, we hypothesize that in the baseline the more severe the patients' cognitive deficit are, the greater their WM capacity improvement would be after applying the anodal Tdcs over right DLPFC.
The investigators plan to recruit 40 patients with chronic schizophrenia. First, the investigators will collect baseline characteristics including disease severity, cognitive deficits and brain connectivity. Then the investigators will adopt a sham-active crossover design for tDCS treatment with the order of the two sessions (sham and active) counterbalanced across participants. The investigators will perform pre- tDCS and post- tDCS assessments of their spatial WM and verbal WM as well as statistical analyses to see if the effect of cognitive enhancement reaches a significant level. In addition, the investigators will explore the possible predictive indicators of effective treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 235
- Shuang-Ho Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Inform consent acquired
- Age 20 to 50
- Right-handed
- Patients with schizophrenia diagnosed according to DSM-5 criteria
Exclusion criteria
- Participants who are pregnant or breastfeeding
- Participants who have metal implants
- Participants who have alcohol/substance use disorder or received electro-convulsive therapy within the past 6 months.
- Participants who have history of head injury with loss of consciousness
- Participants who have history of brain lesions, infection, or epilepsy
- Skin lesions on the electrodes placed
- Cancer patients
- Patients with high fever
- Patients with significant sensory loss
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active comparator
Within group
|
Right DLPC was located as F4 according to the international 10-20 EEG system.
Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm^2).
The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min.
The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition.
The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation.
The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
|
Sham Comparator: Sham comparator
Within group
|
Right DLPC was located as F4 according to the international 10-20 EEG system.
Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm^2).
The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min.
The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition.
The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation.
The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual-spatial working memory span measured by Corsi Block-Tapping task
Time Frame: up to one hour
|
The paradigm was computer-adaptive, and thus the set size would only increase if the participant passed consecutive two trials of the same span.
The lowest span level started from 2 (2 squares that change color) and up to 9 as maximum.
|
up to one hour
|
Verbal working memory measured by digit-span test
Time Frame: up to one hour
|
The paradigm was also computer-adaptive
|
up to one hour
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jiunn-Kae Wang, MD, Taipei Medical University Shuang Ho Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N201701040
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on STARSTIM
-
University of MinnesotaWithdrawn
-
Neuroelectrics CorporationActive, not recruitingMajor Depressive DisorderUnited States
-
Université Catholique de LouvainCompleted
-
University of Texas Southwestern Medical CenterRecruitingDementia | Alzheimer Disease | Mild Cognitive ImpairmentUnited States
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
CHAN SAU MAN, SANDRACompleted
-
Stony Brook UniversityNational Center of Neuromodulation for RehabilitationTerminatedStroke | ApathyUnited States
-
Stony Brook UniversityNational Center for Neuromodulation for RehabilitationTerminatedStroke | Cognitive Impairment | Cognitive Deficit | Short-Term Memory ImpairmentUnited States
-
University of OxfordCompletedInter-individual Variability
-
Hôpital le VinatierCompletedImpulsive Behavior | InhibitionFrance